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Original Article
Rhinocerebral Zygomycosis in Pakistan: Clinical spectrum,
management, and outcome
Mubasher Ikram,1 Moghira Iqbal,2 Muhammad Aslam Khan,3 Erum Khan,4 Mahnaz Shah,5 Raymond A. Smego Jr.6
Departments of Otolaryngology,1,2 Departments of Medicine,3,6 Departments of Microbiology,4
Departments of Ophthalmology,5 The Aga Khan University, Karachi, Pakistan.

Abstract
Objective: To study the disease spectrum and salient management features of 36 patients with
histopathologically-confirmed rhinocerebral zygomycosis seen at our academic center over a 16-year period.
Methods: Retrospective review of patients admitted to the Aga Khan University Hospital in Karachi, Pakistan
from January 1991 to December 2006 with histopathologically-confirmed zygomycosis of the head and neck.
Results: Mean patient age was 40 ± 5.0 years (range, 34-63 years), and 23 (64%) patients were male. Thirtytwo (89%) patients were referred from clinical services other than otolaryngology. Underlying predisposing
conditions included diabetes mellitus (21 patients), haematologic diseases (9), and renal failure (6). Twenty
(55%) patients had limited sinonasal disease, ten (28%) had orbital involvement, and six (17%) had intracranial
extension. All patients underwent rigid nasal endoscopy and biopsy, and black necrotic tissue was seen in 22
(61%) instances warranting endoscopic or open surgical debridement. Four of 6 patients undergoing open
surgery required orbital exenteration. Overall patient survival was 56% (20/36 patients). Diabetic patients had
improved survival (17/21, or 81%) compared to patients with haematologic disorders (3/9, or 33%) (p = 0.001).
All six patients with intracerebral disease died. Eighteen of the 22 (82%) patients treated with surgery plus
amphotericin B survived vs. two of 14 (14%) receiving amphotericin B alone (p < 0.001).
Conclusions: In rhinocerebral zygomycosis, an aggressive, multidisciplinary, diagnostic and therapeutic
approach that utilizes CT or MRI staging, and combines endoscopic or open surgical debridement with
amphotericin B-based antifungal therapy offers the best chance of recovery.
Keywords: Zygomycosis, Mucormycosis, Fungal infection, Rhinocerebral (JPMA 61:477; 2011).

Introduction
Zygomycosis (also known as mucormycosis and
phycomycosis) is a fulminant and invasive opportunistic
infection caused by fungi of the class Zygomycetes, order
Mucorales, family Mucoracae, and genera Mucor, Absidia,
Rhizomucor, Rhizopus, and Cunninghamella, and all agents
have clinically indistinguishable presentations.1 The disease
can present in a number of localized (pulmonary, cutaneous,
or intestinal) or disseminated forms, although the most
common and often lethal form is rhinocerebral zygomycosis,
and it is associated with diabetes mellitus, metabolic acidosis,
debilitation, and immunosuppressive diseases and/or
treatments.2 In this article we herein review our 13-year
experience with 36 cases of histopathologically-confirmed
rhinocerebral zygomycosis at an academic center in Pakistan,
and describe the salient management features of this lifethreatening infection.

Patients and Methods
The medical records of patients, admitted to the Aga
Khan University Hospital in Karachi, Pakistan from January
1991 to December 2006 with histopathologically-confirmed
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zygormycosis of the head and neck, were retrospectively
reviewed. The diagnosis was made in all cases by the
presence of non-septate branching hyphae on histopathologic
sections. Clinical data extracted from inpatient medical
records included presenting signs and symptoms, age, sex,
diagnostic tests and sensitivities, treatment, and disease
course and outcome. Rigid nasal endoscopy and biopsy was
performed on all patients, and tissue was sent for
histopathology, fungal smear (using potassium hydroxide),
and culture on Sabouraud's dextrose agar with incubation at
25ºC and 37ºC. Computed tomography (CT) scanning of the
paranansal sinuses and brain, including axial and coronal
sections was performed in all cases to determine extent of the
disease. An infectious diseases specialist was involved early
in the management of all subjects, and in cases with eye
involvement preoperative and intraoperative opinions from
an ophthalmologist were obtained regarding the viability of
the globe. Following surgery, all patients were followed
closely for disease progression and repeat debridement was
performed where necessary. Surgery was not performed on
patients with intracranial extension. In patients with large
defects following aggressive surgery, reconstruction was
undertaken using loco-regional flaps to cover defects.
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Patients who underwent maxillectomy and/or orbital
exenteration required some type of prosthesis to cover the
anatomic defects.

Table-2: Isolation of Mucor and Rhizopus organisms at
the Aga Khan University Hospital, 1995 -2006.

Results
Thirty-six patients with rhinoorbitocerebral
zygomycosis were seen at our academic center during the
study period; clinical and treatment characteristics for all
cases are shown in Table-1. Mean patient age was 40 ± 5.0
years (range, 34-63 years) and 23 (64%) patients were male.
Thirty-two (89%) patients were referred from clinical
services other than otolaryngology including internal
medicine, infectious diseases, endocrinology, ophthalmology,
and oncology Predisposing conditions included diabetes
mellitus (21 patients; 58%), haematologic diseases (9
patients; 25%), and renal failure (6 patients; 17%). All
patients had rigid nasal endoscopy and biopsy which revealed
black necrotic tissue in 22 (61%) instances, thereby
warranting endoscopic or open surgical debridement. In 36
patients, a presumptive diagnosis of zygomycosis was made
according to characteristic histopathology. Confirmatory
tissue smears were positive for fungal hyphae in 22 (61%)
cases, and 28 (78%) had operative tissue cultures positive for
fungal growth. Causative microorganisms included either
Mucor species (32 isolates) or Rhizopus species (4 isolates).
Table-2 shows isolation data for all zygomycetes at the Aga
Khan University Hospital Mycology Laboratory during the
period 1995-2006.
Twenty (56%) patients had disease limited to
sinonasal regions, ten (28%) had evidence of involvement of
Table-1: Clinical and treatment characteristics for 36 cases
of rhino-cerebral zygomycosis.
Features
Features
Disease extent
Sinonasal
Orbital
Intracranial
Underlying disease
Diabetes mellitus
Haematologic disorders
Chronic renal failure
Causative organism
Mucor spp.
Rhizopus spp.
Treatment
AMB* alone
AMB* plus surgery
Surgery
Endoscopic debridement
Open radical surgery+
None

Patients
(n = 36) (%)

20 (56)
10 (28)
6 (17)
21 (58)
9 (25)
6 (17)
32 (94)
4 (6)
14 (39)
22 (61)
16 (44)
6 (17)
14 (39)

* Amphotericin B.
+ Four of six patients with orbital involvement required orbital exenteration.
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Year isolated
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
Total
Gender
Male
Female
Age group (years)
< 15
15-30
31-45
46-60
> 60
Total
Patient location
Inpatient
Outpatient
Body source
Sinus curettage
Nasal scraping
Nail scraping
Sputum
Bronchial lavage
Bronchial wash
Skin scraping
Tracheal aspirate
Wound/ abscess
Foot
Lung aspirate
Scraping (other)

Mucor spp.
(n = 106)

Rhizopus spp.
(n = 15)

Total
(%)

15
4
8
5
4
11
9
7
10
8
10
15
106 (88)

0
0
0
1
0
0
0
0
1
4
6
3
15 (12)

15
4
8
6
4
11
9
7
11
12
16
18
121 (100)

47
59

8
7

55
66

4
16
29
46
11
106

1
1
3
6
4
15

5
17
32
51
15
120

55
51

9
6

64 (53)
57 (47)

53
18
13
7
5
2
3
2
1
1
0
1

8
4
0
0
0
1
0
0
1
0
1
0

61 (50)
22 (18)
13 (11)
7 (6)
5 (4)
3 (3)
3 (3)
2 (2)
2 (2)
1 (0.5)
1 (0.5)
1 (0.5)

the orbit at the time of initial presentation, and six (17%)
patients had intracranial extension. All patients received
amphotericin B within 48 hours of presentation based upon
clinical suspicion of the disease. Most patients received a
cumulative dose of 2-3 g of amphotericin B during the course
of their treatment. A majority received maintenance iv
amphotericin B infusions at home by home care nurses or in
the hospital day care unit for periods up to several months
depending on the clinical and radiologic response to therapy
and degree of drug-related side effects. Almost all patients
tolerated drug therapy well without any prolonged
interruptions in therapy, and none suffered any significant
long-term adverse drug effects. Nephrotoxic effects of
amphotericin B were reversible and managed by ensuring
adequate daily hydration with iv normal saline prior to daily
478

Table-3: Clinical outcomes for 36 patients with invasive zygomycosis.

Feature
Diabetic
Yes
No
Causative organism
Mucor spp.
Rhizopus spp.
Treatment
Surgery + AMB*
AMB* alone

Survived
(n = 20)

No. of patients (%)
Died
(n = 16)

p value

17 (85)
3 (15)

4 (25)
12 (75)

0.001
NS

17 (85)
3 (15)

15 (94)
1 (6)

NS
NS

18 (90)
2 (10)

4 (25)
12 (75)

< 0.001
NS

* Amphotericin B.

infusions, and by withholding therapy for a few days during
periods of transient escalating azotaemia.
Endoscopic debridement alone was performed in 16
(44%) patients, and six (17%) subjects required open/radical
surgical procedures like Caldwell-Luc, facial debridement,
and/or hemimaxillectomy. Four of the patients undergoing
open surgery required orbital exenteration. Three patients
required more then one surgical debridement, and one patient
underwent three debridements. In fourteen patients (39%)
surgery was not performed due to an advanced stage of
disease or poor medical condition, or due to refusal by the
patient or family.
Clinical outcomes for all 36 patients with invasive
zygomycosis are summarized in Table-3. The overall patient
survival was 56% (20 of 36 patients). Among the 16 deaths,
six patients had intracranial extension of disease and six had
underlying haematologic disorders (including one patient
with extensive faciocutanous zygomycosis and acute
leukaemia) and four had chronic renal failure. Diabetic
patients had a better outcome in our series: 17 of 21 (81%)
survived compared to 3 of 9 (33%) patients with underlying
haematologic conditions (p = 0.001). All six patients with
intracranial extension died. Eighteen of 22 (82%) patients
treated with surgery plus amphotercin B survived vs. two of
14 (14%) receiving amphotercin B alone (p < 0.001).

Discussion
Zygomycosis involving the upper airway was first
described in 1885 by Paltauf, who named it mycosis
mucornia.3 In 1943, Gregory and colleagues reported the
characteristic findings of advanced rhinocerebral
zygomycosis in three patients with diabetic ketoacidosis4 and
Harris reported the first cure of this disease in 1955.5
Timely diagnosis and successful management of
mucormycosis requires a coordinated, multidisciplinary
approach
employing
reversal
of
underlying
immunosuppression, correction of metabolic acidosis,
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aggressive surgical intervention and systemic antifungal
therapy, and the assistance of otolaryngologists,
ophthalmologists, radiologists, internists, and infections
disease and/or oncology specialists. Zygomycosis should be
regarded as a medical-surgical emergency; antifungal therapy
should be initiated at the slightest suggestion of infection, and
patients should undergo endoscopic evaluation without delay,
in order to visualize sinonasal structures and obtain
appropriate specimens for histopathologic and microbiologic
sampling. Direct nasal smear examination and fungal cultures
are helpful in diagnosis, but if negative do not exclude the
disease. Intraoperative frozen section is a specific and
sensitive method of making a rapid diagnosis of rhinocerebral
zygomycosis. In tissue biopsy, identification of non-septate,
branching (at 90 degrees) hyphae without granuloma
formation confirms the diagnosis. Fine-needle aspiration
cytology appears to represent a useful alternative to tissue
biopsy.6 Computed tomography or magnetic resonance
imaging (MRI) is recommended for staging the extent of
disease, and infiltration of periantral fat planes may represent
the earliest imaging evidence of invasive fungal disease and
should suggest the possibility of invasive fungal sinusitis in
the appropriate clinical setting.7 Adequate debridement
involves removal of all devitalized tissue up to healthy or
bleeding margins,7 and multiple debridements may be
necessary in some patients.1
Amphotericin B is the drug of choice for medical
management of zygomycosis, although side effects including
nephrotoxicity may require dose adjustment or limit use.
Lipid-based formulations such as liposomal amphotericin B,
amphotericin B lipid complex,8,9 and amphotericin B
colloidal dispersion10,11 can be given in higher doses than
amphotericin B deoxycholate and are associated with reduced
side effects, most importantly dose-limiting renal toxicity.
The imidazole, itraconazole, has in vitro activity against the
etiologic agents of mucormycosis, but there is extremely
limited clinical experience with its use.12 In vitro and in vivo
resistance of zygomycetes to the triazole, voriconazole, have
been associated with mucormycosis breakthrough in
immunosuppressed populations in which the drug is used for
antifungal prophylaxis.13 In the largest collection of in vitro
susceptibility data for clinical isolates of zygomycetes,
amphotericin B was the most active antifungal agent tested.14
The significant in vitro activity of the new triazole,
posaconazole, against several species appears to support its
reported, albeit limited, clinical efficacy. Early case reports
indicate that posacanzole may be a useful drug for patients
with rhinocerebral zygomycosis, including disease refractory
to amphotermicn B.15-17 Other rarely reported adjuncts to
systemic antifungal therapy for mucormycosis include
nebulized amphotericin B, granulocyte macrophage-colony
stimulating factor, and hyperbaric oxygen therapy.18-20
J Pak Med Assoc

Good prognostic factors for rhinocerebral
zygomycosis include early diagnosis and initiation of
treatment21 and correction of underlying metabolic
acidosis,22 while poor prognostic features include facial
necrosis and nasal deformity21 and intracranial extension.21,23
Unlike an earlier report but similar to findings reported by
Blitzer et al,21 we found that patients with diabetes mellitus
had a better outcome than those with haematologic disorders
including leukaemia.23 Early diagnostic markers of infection
include perinasal cellulitis and paresthesia, periorbital
oedema, mucopurulent rhinorrhea, and nasal crusting.7
Our successful results with endoscopic sinus surgery
confirms those previously reported in the literature, and
demonstrate that this modality can be used alone or in
combination with traditional open surgical procedures.24 The
82% survival rate seen in our patients with rhinocerebral
zygomycosis treated with surgery plus antifungal therapy was
similar to results reported in a study of 20 patients from
Taiwan.25 Fifteen of 16 (94%) patients reported by Khor and
coworkers who received surgical debridement combined with
amphotericin B survived, compared to only one (20%) of 5
patients who received amphotericin B alone (p = 0.004).25 A
delay in diagnosis was also associated with higher disease
mortality (p = 0.028). Only 3 of 12 (25%) patients with
rhinocerebral disease from Greece survived their infection,2
and all six of our patients with intracranial extension died.
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